

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SHANGHAI JUNSHI BIOSCIENCES CO., LTD.*

上海君實生物醫藥科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1877)

PROPOSED APPOINTMENT OF EXECUTIVE DIRECTOR AND RESIGNATION OF NON-EXECUTIVE DIRECTOR

This announcement is made by Shanghai Junshi Biosciences Co., Ltd.* (the “**Company**”) pursuant to Rule 13.51(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”). Reference is also made to the overseas regulatory announcement dated 30 August 2023.

(1) Proposed appointment of executive director of the Company

The board of directors of the Company (the “**Board**”) has considered and approved to nominate Dr. Wang Gang (“**Dr. Wang**”) as a candidate for executive director of the Company (“**Director**”). The appointment of Dr. Wang as executive Director will be proposed for consideration and approval by the shareholders of the Company (“**Shareholders**”) at the general meeting of the Company.

The biography of Dr. Wang is as follows:

Dr. Wang Gang (王剛), aged 66, obtained a Ph.D degree in Pharmacology and Toxicology from the School of Medicine of Dartmouth College in the United States in September 1995.

He has been serving as the deputy general manager of the Company since 29 August 2019. He has also been serving as an independent director of Obio Technology (Shanghai) Corp., Ltd.* (和元生物技術(上海)股份有限公司) since December 2020, and independent director of Hrain Biotechnology Co., Ltd.* (上海恒潤達生生物科技股份有限公司) since June 2021.

Prior to joining the Company, he served as a postdoctoral researcher at the National Institutes of Health from October 1995 to June 1998. From June 1998 to July 1999, he served as a research scientist at Osiris Therapeutics in the United States. From August 1999 to August 2003, he served as a biologist at the National Institutes of Health. From August 2003 to June 2005, he served as an assistant professor at the University of Texas. From June 2005 to April 2017, he served in various positions, including the senior policy advisor, assistant director of the China office, senior reviewer and presiding officer, at the United States Food And Drug Administration. From April 2017 to April 2018, he served as the chief scientist in charge of compliance and inspection at the Drug Evaluation Center of the China Food and Drug Administration (CFDA). From May 2018 to August 2019, he served as the vice president for quality (Shanghai) at Wuxi Co.* (無錫藥明生物技術股份有限公司).

As at the date of this announcement, Dr. Wang is deemed to be interested in 172,000 A shares of the Company (“**A Shares**”) within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), representing 0.00029% and 0.00022% of the total number of issued A shares and issued share capital of the Company, respectively. 10,000 A Shares out of the 172,000 A Shares are directly held by Dr. Wang. He was granted 270,000 restricted A Shares on 16 November 2020 under the 2020 Restricted A Share Incentive Scheme adopted by the Company on 29 September 2020. Out of the 270,000 restricted A Shares, 108,000 restricted A Shares have been nullified on 16 November 2022. Hence, Dr. Wang remains to be interested in 162,000 restricted A Shares.

As at the date of this announcement, save as disclosed above, Dr. Wang has confirmed that he: (i) does not hold any position in the Company or any other subsidiaries of the Company, nor did he hold any directorship or positions of supervisor in any other listed companies in Hong Kong or overseas in the last three years; (ii) does not have any relationship with any directors, supervisors, senior management or substantial or controlling shareholders (as defined in the Listing Rules) of the Company; and (iii) does not have any interests in the shares or underlying shares of the Company or any of its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

If Dr. Wang is appointed as an executive Director at the general meeting of the Company, the Company will enter into a service contract with Dr. Wang in relation to his appointment as an executive Director for a term commencing from the date of approval of his appointment at the general meeting of the Company and expiring on the conclusion of the third session of the Board, which is subject to retirement by rotation and re-appointment in accordance with the articles of association of the Company and the Listing Rules. The remuneration of Dr. Wang will be determined with reference to his duties and responsibilities in the Company and prevailing market conditions, and will be subject to review by the Board and the Remuneration and Appraisal Committee of the Company from time to time. Dr. Wang has not entered into nor proposed to enter into any service contracts, which fall within the meaning of Rule 13.68 of the Listing Rules requiring the prior approval of Shareholders at general meetings, with the Company.

Save as disclosed above, there are no other matters concerning Dr. Wang’s appointment as an executive Director that need to be brought to the attention of the Shareholders nor any information required to be disclosed pursuant to the requirements of Rule 13.51(2)(h) to (v) of the Listing Rules.

The appointment of Dr. Wang as an executive Director is subject to the approval of the Shareholders by way of ordinary resolution at the general meeting of the Company. Notice of the general meeting and a circular containing, among other things, details of the above proposal will be despatched to the Shareholders in due course.

(2) Resignation of non-executive director of the Company

Dr. Wu Hai (“**Dr. Wu**”) has tendered his resignation as a non-executive director of the Company with effect from 30 August 2023 due to other work arrangements.

Dr. Wu has confirmed that he has no disagreement with the Board and there are no other matters that should be brought to the attention of the Shareholders in relation to his resignation.

The Board would like to take this opportunity to express its sincere gratitude to Dr. Wu for his contributions to the Company during his tenure of office.

By order of the Board
Shanghai Junshi Biosciences Co., Ltd.*
Mr. Xiong Jun
Chairman

Shanghai, the PRC, 30 August 2023

As at the date of this announcement, the board of directors of the Company comprises Mr. Xiong Jun, Dr. Li Ning, Dr. Feng Hui, Mr. Zhang Zhuobing, Dr. Yao Sheng, Mr. Li Cong and Dr. Zou Jianjun as executive Directors; Mr. Tang Yi as non-executive Director; and Dr. Roy Steven Herbst, Mr. Qian Zhi, Mr. Zhang Chun, Dr. Feng Xiaoyuan and Dr. Meng Anming as independent non-executive Directors.

* *For identification purpose only*